Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

IntelGenx (V.IGX) obtains further U.S. patent for proprietary drug delivery tech

Stockhouse Editorial
0 Comments| April 16, 2014

IntelGenx (TSX:V.IGX, Stock Forum), a Saint Laurent Quebec-based drug delivery firm engaged in the development of novel, orally administered drug delivery products based on its proprietary drug delivery technologies, announced today that the company had received an a Notice of Allowance (“NOA”) from the United States Patent and Trademark Office (“USPTO”) covering its proprietary AdVersa(TM) mucoadhesive drug delivery technology.


According to the news release, “This NOA concludes the examination of the U.S. patent application and will result in the issuance of a U.S. patent after the administrative process is completed.”


Company president and CEO, Rajiv Khosla, commented, “This patent allowance by the USPTO is another important achievement in protecting the innovation and commercial potential of IntelGenx drug delivery technologies and products.”


He then concluded, “This NOA is the latest example of how our scientific innovation continues to establish IntelGenx as a leader in pharmaceutical drug delivery.”

Rate this article
0 stars



Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.


You are already a member! Please enter your password to sign in.


No comments yet. Be first to comment!

Leave a Message

You must be logged in to access this feature.